Lynparza approved by EMA for epithelial ovarian, fallopian tube or primary peritoneal cancer

In the Headlines: Missing record of NCAB meetings restored to NIH website

In this episode of The Cancer Letter Podcast, Jacquelyn and Paul talk about the first meeting of the National Cancer Advisory Board, the uncertainty of cancer registries, and about choosing what to cover as the Trump administration “floods the zone.”

June 18, 2025

Podcast

The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it”

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers.

June 13, 2025

Vol.51 No.23

By Paul Goldberg

Capitol Hill

Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheaval
Susan Collins: Trump’s 40% cut is “so disturbing”

In a 96-minute hearing in front of the Senate Appropriations Committee on the Trump administration’s budget, senators slammed NIH Director Jay Bhattacharya for not taking responsibility for the funding cuts to research and upheaval at NIH.

June 13, 2025

Vol.51 No.23

By Claire Marie Porter

Regulatory News

In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times
“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

CRC patients with cannabis use disorder may have higher odds of death within five years of diagnosis
Observational study suggests that clinicians should be cautious when recommending cannabis to manage cancer symptoms

Cannabis use disorder is associated with a dramatically increased odds of death within five years of diagnosis in people with colorectal cancer, a recent observational study found.

June 13, 2025

Vol.51 No.23

By Jacquelyn Cobb

Insights from ASCO 2025: Real-world evidence drives clinical decision-making

City of Hope researchers presented compelling real-world evidence and novel combination therapies at the 2025 ASCO Annual Meeting, with findings that could reshape treatment approaches for breast, colorectal, renal, and prostate cancers.

June 13, 2025

Vol.51 No.23

By City of Hope

Lynparza approved by EMA for epithelial ovarian, fallopian tube or primary peritoneal cancer

YOU MAY BE INTERESTED IN

In the Headlines: Missing record of NCAB meetings restored to NIH website

The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it”

Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheaval
Susan Collins: Trump’s 40% cut is “so disturbing”

In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times
“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”

CRC patients with cannabis use disorder may have higher odds of death within five years of diagnosis
Observational study suggests that clinicians should be cautious when recommending cannabis to manage cancer symptoms

Insights from ASCO 2025: Real-world evidence drives clinical decision-making

Renew today!

Subscriber content

Never miss an issue!

Login

Lynparza approved by EMA for epithelial ovarian, fallopian tube or primary peritoneal cancer

YOU MAY BE INTERESTED IN

In the Headlines: Missing record of NCAB meetings restored to NIH website

The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woesDirectors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it”

Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheavalSusan Collins: Trump’s 40% cut is “so disturbing”

In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”

CRC patients with cannabis use disorder may have higher odds of death within five years of diagnosisObservational study suggests that clinicians should be cautious when recommending cannabis to manage cancer symptoms

Insights from ASCO 2025: Real-world evidence drives clinical decision-making

Never miss an issue!

Login

The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it”

Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheaval
Susan Collins: Trump’s 40% cut is “so disturbing”

In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times
“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”

CRC patients with cannabis use disorder may have higher odds of death within five years of diagnosis
Observational study suggests that clinicians should be cautious when recommending cannabis to manage cancer symptoms